Table 1.

Recommendation questions

Recommendation questions
1a. Should adults with newly diagnosed ITP and a platelet count of <30 × 109/L who are asymptomatic or have minor mucocutaneous bleeding be treated with corticosteroids or observation?
1b. Should adults with newly diagnosed ITP and a platelet count of ≥30 × 109/L who are asymptomatic or have minor mucocutaneous bleeding be treated with corticosteroids or observation?
2a. Should adults with ITP and a platelet count <20 × 109/L who are asymptomatic or have mild mucocutaneous bleeding be treated as an outpatient or be admitted to the hospital?
2b. Should adults with ITP and a platelet count ≥20 × 109/L who are asymptomatic or have mild mucocutaneous bleeding be treated as an outpatient or be admitted to the hospital?
3. Should adults with newly diagnosed ITP be treated with a short course (≤6 wk) or a prolonged course (>6 wk including treatment and taper) of prednisone as initial treatment?
4. Should adults with newly diagnosed ITP be treated with prednisone (0.5-2 mg/kg/d) or dexamethasone (40 mg/d × 4 d) as the type of corticosteroid for initial therapy?
5. Should adults with newly diagnosed ITP be treated with rituximab with corticosteroids or corticosteroids alone for initial therapy?
6. Should adults with ITP for ≥3 mo who are corticosteroid-dependent or have no response to corticosteroids and are going to be treated with a TPO-RA receive eltrombopag or romiplostim?
7. Should adults with ITP lasting ≥3 mo who are corticosteroid-dependent or have no response to corticosteroids undergo splenectomy or be treated with a TPO-RA?
8. Should adults with ITP lasting ≥3 mo who are corticosteroid-dependent or have no response to corticosteroids undergo splenectomy or be treated with rituximab?
9. Should adults with ITP lasting ≥3 mo who are corticosteroid-dependent or have no response to corticosteroids be treated with rituximab or a TPO-RA?
10a. Should children with newly diagnosed ITP and a platelet count of <20 × 109/L who have no or mild bleeding (skin manifestations) be treated as outpatients or admitted to the hospital?
10b. Should children with newly diagnosed ITP and a platelet count ≥20 × 109/L who have no or mild bleeding (skin manifestations) be treated as outpatients or admitted to the hospital?
11. Should children with newly diagnosed ITP who have no or minor bleeding be treated with observation or corticosteroids for initial therapy?
12. Should children with newly diagnosed ITP who have no or minor bleeding be treated with observation or IVIG?
13. Should children with newly diagnosed ITP who have no or minor bleeding be treated with observation or anti-D immunoglobulin for initial therapy?
14. Should children with newly diagnosed ITP who have non–life-threatening bleeding and/or diminished HRQoL receive a course of corticosteroids longer than 7 d vs 7 d or shorter?
15. Should children with newly diagnosed ITP who have non–life-threatening mucosal bleeding and/or diminished HRQoL receive dexamethasone (0.6 mg/kg/d; maximum, 40 mg/d × 4 d) or prednisone (2-4 mg/kg/d for 5-7 d; maximum, 120 mg daily, for 5-7 d)?
16. Should children with newly diagnosed ITP who have non–life-threatening mucosal bleeding and/or diminished HRQoL be treated with anti-D immunoglobulin or corticosteroids for initial therapy?
17. Should children with newly diagnosed ITP who have non–life-threatening mucosal bleeding and/or diminished HRQoL be treated with IVIG or anti-D immunoglobulin for initial therapy?
18. Should children with newly diagnosed ITP who have non–life-threatening-mucosal bleeding and/or diminished HRQoL be treated with IVIG or corticosteroids?
19. Should children with ITP who have non–life-threatening mucosal bleeding and/or diminished HRQoL and do not respond to first-line treatment be treated with TPO-RAs or rituximab?
20. Should children with ITP who have non–life-threatening mucosal bleeding and/or diminished HRQoL and do not respond to first-line treatment be treated with TPO-RAs or splenectomy?
21. Should children with ITP who have non–life-threatening mucosal bleeding and/or diminished HRQoL and do not respond to first-line treatment be treated with rituximab or splenectomy?